Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

SLXP 172.81
price chart
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
Salix Pharmaceuticals, Ltd. (SLXP) Attracts Endo International's (ENDP) Attention
... is in the race to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), anonymous sources told Reuters. Endo, which focuses on pain management drugs, sent several letters to Salix, maker of drugs for bowel diseases, only to be rebuffed on many accounts.
Valeant Said to Secure Salix Financing, Closing In on Offer  Bloomberg
Bullish Salix Analyst Says Shares are Fairly Valued Absent a Deal  Wall Street Journal (blog)
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Jefferies Sees Acquisition Of Salix Pharmaceuticals As Being Even More ...  Benzinga
Salix Pharmaceuticals Reports 3Q2014 Results  MarketWatch
Related articles »  
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Salix Pharmaceuticals Announces 4Q and FY2014 Financial Results ...  Business Wire (press release)
Salix Pharmaceuticals Cut to "Neutral" at Sterne Agee (SLXP)  The Legacy
Salix Pharmaceuticals, Ltd Downgraded At UBS
UBS downgrades Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) stock from a Buy to a Hold rating, but increases its price target from $144 to $158.
Salix Pharmaceuticals (SLXP) Stock Price Target Increased Today at Cantor ...  TheStreet.com
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) close to 52-week high on important ...  Markets Wired
Benzinga's Top Downgrades  Benzinga
Salix Pharmaceuticals, Ltd. (SLXP) Q4 Revenue Hits A Record Low
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) on Monday announced its fourth-quarter financial results for fiscal'14 (4QFY14), registering a hefty decline in revenue as it ceases sales to wholesalers.
The Revenue of Q4 of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Reveals ...  WallStreet.org
What to Expect When Salix Pharmaceuticals (SLXP) Reports Fourth Quarter ...  TheStreet.com
Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from ...
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) (�Salix� or the �Company�) today confirmed that it has received an unsolicited proposal from Endo International plc (�Endo�) to acquire all of the outstanding shares of common stock of the Company for a ...
Valeant Pharmaceuticals Teams Up With Ackman As The Salix Pharmaceuticals ...  Bidness ETC
Thursday's Vital Data: Intel Corporation (INTC), Qualcomm, Inc. (QCOM ...  Investorplace.com
Endo International plc - Ordinary Shares Tries To Woo Salix Pharmaceuticals ...
Endo International plc (NASDAQ:ENDP) seems ready to play the spoiler role as it closes in on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), which was until recently being publicly eyed only by Valeant Pharmaceuticals Intl Inc (NYSE:VRX), who has extended ...
Valeant Pharmaceuticals International Inc's bid for Salix ...  Financial Post
Surprise Rival Bid Emerges for Salix  Wall Street Journal
Salix Pharmaceuticals, Ltd. Stockholders Encouraged to Contact Securities Law ...
27, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating the board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) in connection with a buyout for only $158.00 per share. Concerned SLXP investors are encouraged to contact ...